{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:26:16Z","timestamp":1792700776493,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-67415-y","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:45:10Z","timestamp":1766054710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4385-6706","authenticated-orcid":false,"given":"Mengxi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3682-2141","authenticated-orcid":false,"given":"Mengting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8444-1537","authenticated-orcid":false,"given":"Jianxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5560","authenticated-orcid":false,"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huining","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"67415_CR1","doi-asserted-by":"publisher","first-page":"904133","DOI":"10.3389\/fimmu.2022.904133","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang, G. & Wang, W. Advanced cell therapies for glioblastoma [J]. Front. Immunol. 13, 904133\u2013904149 (2022).","journal-title":"Front. Immunol."},{"key":"67415_CR2","doi-asserted-by":"publisher","first-page":"927132","DOI":"10.3389\/fimmu.2022.927132","volume":"13","author":"P Zhang","year":"2022","unstructured":"Zhang, P., Zhang, Y. & Ji, N. Challenges in the treatment of glioblastoma by chimeric antigen receptor T-cell immunotherapy and possible solutions [J]. Front. Immunol. 13, 927132\u2013927145 (2022).","journal-title":"Front. Immunol."},{"key":"67415_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/neuonc\/noad258","volume":"26","author":"CL Tseng","year":"2024","unstructured":"Tseng, C. L. et al. Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: a new future is on the horizon [J]. Neuro Oncol. 26, S3\u2013S16 (2024).","journal-title":"Neuro Oncol."},{"key":"67415_CR4","doi-asserted-by":"publisher","first-page":"663092","DOI":"10.3389\/fncel.2021.663092","volume":"15","author":"JS So","year":"2021","unstructured":"So, J. S., Kim, H. & Han, K. S. Mechanisms of invasion in glioblastoma: extracellular matrix, Ca(2+) signaling, and glutamate [J]. Front. Cell. Neurosci. 15, 663092\u2013663102 (2021).","journal-title":"Front. Cell. Neurosci."},{"key":"67415_CR5","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/cancers16142500","volume":"16","author":"T Pan","year":"2024","unstructured":"Pan, T. et al. Glioma-stem-cell-derived exosomes remodeled glioma-associated macrophage via NEAT1\/miR-125a\/STAT3 pathway [J]. Cancers 16, 2500\u20132518 (2024).","journal-title":"Cancers"},{"key":"67415_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jconrel.2017.08.019","volume":"264","author":"C Bastiancich","year":"2017","unstructured":"Bastiancich, C. et al. Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection [J]. J. Control. Release 264, 45\u201354 (2017).","journal-title":"J. Control. Release"},{"key":"67415_CR7","doi-asserted-by":"publisher","first-page":"e2106606","DOI":"10.1002\/adma.202106606","volume":"34","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Silk microneedle patch capable of on-demand multidrug delivery to the brain for glioblastoma treatment [J]. Adv. Mater. 34, e2106606\u2013e2106618 (2022).","journal-title":"Adv. Mater."},{"key":"67415_CR8","doi-asserted-by":"publisher","first-page":"122341","DOI":"10.1016\/j.ijpharm.2022.122341","volume":"628","author":"E Bozzato","year":"2022","unstructured":"Bozzato, E. et al. Dual-drug loaded nanomedicine hydrogel as a therapeutic platform to target both residual glioblastoma and glioma stem cells [J]. Int. J. Pharm. 628, 122341\u2013122353 (2022).","journal-title":"Int. J. Pharm."},{"key":"67415_CR9","doi-asserted-by":"publisher","first-page":"7979","DOI":"10.3390\/ijms25147979","volume":"25","author":"E Agosti","year":"2024","unstructured":"Agosti, E. et al. Glioma stem cells as promoter of glioma progression: a systematic review of molecular pathways and targeted therapies [J]. Int. J. Mol. Sci. 25, 7979\u20138002 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"67415_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/cancers16010102","volume":"16","author":"V Ramar","year":"2023","unstructured":"Ramar, V. et al. Progress in glioma stem cell research [J]. Cancers 16, 102\u2013130 (2023).","journal-title":"Cancers"},{"key":"67415_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s13046-019-1319-4","volume":"38","author":"L Yi","year":"2019","unstructured":"Yi, L. et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12\/CXCR4 [J]. J. Exp. Clin. Cancer Res. 38, 339\u2013354 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"67415_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10571-019-00771-8","volume":"40","author":"Z Sun","year":"2020","unstructured":"Sun, Z. et al. Glioblastoma stem cell-derived exosomes enhance stemness and tumorigenicity of glioma cells by transferring Notch1 protein [J]. Cell. Mol. Neurobiol. 40, 767\u2013784 (2020).","journal-title":"Cell. Mol. Neurobiol."},{"key":"67415_CR13","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1038\/s41467-023-41663-2","volume":"14","author":"J Yin","year":"2023","unstructured":"Yin, J. et al. Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas [J]. Nat. Commun. 14, 5913\u20135928 (2023).","journal-title":"Nat. Commun."},{"key":"67415_CR14","doi-asserted-by":"publisher","first-page":"111058","DOI":"10.1016\/j.biopha.2020.111058","volume":"133","author":"S Datta","year":"2021","unstructured":"Datta, S. et al. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells [J]. Biomed. Pharmacother. 133, 111058\u2013111083 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"67415_CR15","doi-asserted-by":"publisher","first-page":"2182254","DOI":"10.1080\/10717544.2023.2182254","volume":"30","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. Tumor microenvironment-responsive micelles assembled from a prodrug of mitoxantrone and 1-methyl tryptophan for enhanced chemo-immunotherapy [J]. Drug Deliv. 30, 2182254\u20132182266 (2023).","journal-title":"Drug Deliv."},{"key":"67415_CR16","doi-asserted-by":"publisher","first-page":"13929","DOI":"10.3390\/ijms232213929","volume":"23","author":"M Gabel","year":"2022","unstructured":"Gabel, M. et al. Surface design options in polymer- and lipid-based siRNA nanoparticles using antibodies [J]. Int. J. Mol. Sci. 23, 13929\u201313951 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67415_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.tcb.2023.06.006","volume":"34","author":"SB Arya","year":"2024","unstructured":"Arya, S. B., Collie, S. P. & Parent, C. A. The ins-and-outs of exosome biogenesis, secretion, and internalization [J]. Trends Cell Biol. 34, 90\u2013108 (2024).","journal-title":"Trends Cell Biol."},{"key":"67415_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","volume":"15","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh, M. D. A. et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling [J]. J. Hematol. Oncol. 15, 83\u2013122 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"67415_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jconrel.2019.11.005","volume":"316","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes [J]. J. Control. Release 316, 381\u2013392 (2019).","journal-title":"J. Control. Release"},{"key":"67415_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives [J]. J. Hematol. Oncol. 17, 31\u2013112 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"67415_CR21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/ijms23052509","volume":"23","author":"E Codrici","year":"2022","unstructured":"Codrici, E. et al. Friends with benefits: chemokines, glioblastoma-associated microglia\/macrophages, and tumor microenvironment [J]. Int. J. Mol. Sci. 23, 2509\u20132545 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67415_CR22","doi-asserted-by":"publisher","first-page":"eabi8075","DOI":"10.1126\/sciadv.abi8075","volume":"8","author":"DS Jones","year":"2022","unstructured":"Jones, D. S. et al. Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy [J]. Sci. Adv. 8, eabi8075\u2013eabi8092 (2022).","journal-title":"Sci. Adv."},{"key":"67415_CR23","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","volume":"184","author":"S Kaczanowska","year":"2021","unstructured":"Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis [J]. Cell 184, 2033\u20132052 (2021).","journal-title":"Cell"},{"key":"67415_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","volume":"19","author":"M Liu","year":"2024","unstructured":"Liu, M. et al. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity [J]. Nat. Nanotechnol. 19, 565\u2013575 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"67415_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jconrel.2022.03.050","volume":"345","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma [J]. J. Control. Release 345, 786\u2013797 (2022).","journal-title":"J. Control. Release"},{"key":"67415_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.nec.2020.12.004","volume":"32","author":"KE Kunigelis","year":"2021","unstructured":"Kunigelis, K. E. & Vogelbaum, M. A. Therapeutic delivery to central nervous system [J]. Neurosurg. Clin. N. Am. 32, 291\u2013303 (2021).","journal-title":"Neurosurg. Clin. N. Am."},{"key":"67415_CR27","doi-asserted-by":"publisher","first-page":"114853","DOI":"10.1016\/j.addr.2023.114853","volume":"197","author":"S Padmakumar","year":"2023","unstructured":"Padmakumar, S. & Amiji, M. M. Long-acting therapeutic delivery systems for the treatment of gliomas [J]. Adv. Drug Deliv. Rev. 197, 114853\u2013114884 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"67415_CR28","doi-asserted-by":"publisher","first-page":"113951","DOI":"10.1016\/j.addr.2021.113951","volume":"177","author":"C Bastiancich","year":"2021","unstructured":"Bastiancich, C. et al. Rationally designed drug delivery systems for the local treatment of resected glioblastoma [J]. Adv. Drug Deliv. Rev. 177, 113951\u2013113978 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"67415_CR29","first-page":"e59718","volume":"16","author":"Y Kawaguchi","year":"2024","unstructured":"Kawaguchi, Y. et al. Unmanageable cerebrospinal fluid leakage with eosinophilic meningitis in a gliadel wafer implant patient [J]. Cureus 16, e59718\u2013e59724 (2024).","journal-title":"Cureus"},{"key":"67415_CR30","doi-asserted-by":"publisher","first-page":"127278","DOI":"10.1016\/j.ijbiomac.2023.127278","volume":"253","author":"YQ Almajidi","year":"2023","unstructured":"Almajidi, Y. Q. et al. Advances in chitosan-based hydrogels for pharmaceutical and biomedical applications: a comprehensive review [J]. Int. J. Biol. Macromol. 253, 127278\u2013127293 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"67415_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2217\/fon-2023-0702","volume":"20","author":"IY Lee","year":"2024","unstructured":"Lee, I. Y. et al. Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients [J]. Future Oncol. 20, 579\u2013591 (2024).","journal-title":"Future Oncol."},{"key":"67415_CR32","doi-asserted-by":"publisher","first-page":"13510","DOI":"10.3390\/ijms232113510","volume":"23","author":"ML Sheu","year":"2022","unstructured":"Sheu, M. L. et al. Potential therapeutic effects of thiazolidinedione on malignant glioma [J]. Int. J. Mol. Sci. 23, 13510\u201313530 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67415_CR33","doi-asserted-by":"publisher","first-page":"608082","DOI":"10.3389\/fonc.2020.608082","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. MELK inhibition effectively suppresses growth of glioblastoma and cancer stem-like cells by blocking AKT and FOXM1 pathways [J]. Front. Oncol. 10, 608082\u2013608096 (2020).","journal-title":"Front. Oncol."},{"key":"67415_CR34","doi-asserted-by":"publisher","first-page":"1903290","DOI":"10.1002\/advs.201903290","volume":"7","author":"G Jiang","year":"2020","unstructured":"Jiang, G. et al. Tailored lipoprotein-like miRNA delivery nanostructure suppresses glioma stemness and drug resistance through receptor-stimulated macropinocytosis [J]. Adv. Sci. 7, 1903290\u20131903304 (2020).","journal-title":"Adv. Sci."},{"key":"67415_CR35","doi-asserted-by":"publisher","first-page":"608911","DOI":"10.3389\/fonc.2020.608911","volume":"10","author":"K Liu","year":"2020","unstructured":"Liu, K., Tsung, K. & Attenello, F. J. Characterizing cell stress and GRP78 in glioma to enhance tumor treatment [J]. Front. Oncol. 10, 608911\u2013608928 (2020).","journal-title":"Front. Oncol."},{"key":"67415_CR36","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.molpharmaceut.3c01228","volume":"21","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Synthesis and evaluation of [(18)F]AlF-NOTA-c-(D)VAP: a novel PET probe for imaging GRP78 in cancer [J]. Mol. Pharm. 21, 2425\u20132434 (2024).","journal-title":"Mol. Pharm."},{"key":"67415_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jconrel.2022.03.047","volume":"345","author":"S Wu","year":"2022","unstructured":"Wu, S. et al. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals [J]. J. Control. Release 345, 685\u2013695 (2022).","journal-title":"J. Control. Release"},{"key":"67415_CR38","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41419-018-0957-3","volume":"9","author":"Z Tao","year":"2018","unstructured":"Tao, Z. et al. Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation [J]. Cell Death Dis. 9, 1063\u20131077 (2018).","journal-title":"Cell Death Dis."},{"key":"67415_CR39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00221-023-06693-8","volume":"241","author":"G Zhao","year":"2023","unstructured":"Zhao, G. et al. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway [J]. Exp. Brain Res. 241, 2409\u20132418 (2023).","journal-title":"Exp. Brain Res."},{"key":"67415_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","volume":"22","author":"J White","year":"2024","unstructured":"White, J. et al. The tumour microenvironment, treatment resistance and recurrence in glioblastoma [J]. J. Transl. Med. 22, 540\u2013554 (2024).","journal-title":"J. Transl. Med."},{"key":"67415_CR41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12935-024-03234-3","volume":"24","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion [J]. Cancer Cell Int. 24, 60\u201375 (2024).","journal-title":"Cancer Cell Int."},{"key":"67415_CR42","doi-asserted-by":"publisher","first-page":"e2310163","DOI":"10.1002\/advs.202310163","volume":"11","author":"T Li","year":"2024","unstructured":"Li, T. et al. Metabolism\/immunity dual-regulation thermogels potentiating immunotherapy of glioblastoma through lactate-excretion inhibition and PD-1\/PD-L1 blockade [J]. Adv. Sci. 11, e2310163\u2013e2310177 (2024).","journal-title":"Adv. Sci."},{"key":"67415_CR43","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41565-020-00843-7","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection [J]. Nat. Nanotechnol. 16, 538\u2013548 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"67415_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-024-03231-4","volume":"43","author":"C Bastiancich","year":"2024","unstructured":"Bastiancich, C. et al. Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment [J]. J. Exp. Clin. Cancer Res. 43, 311\u2013336 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"67415_CR45","doi-asserted-by":"publisher","first-page":"1274587","DOI":"10.3389\/fonc.2023.1274587","volume":"13","author":"K Szklener","year":"2023","unstructured":"Szklener, K. et al. Enhancing glioblastoma treatment through the integration of tumor-treating fields [J]. Front. Oncol. 13, 1274587\u20131274597 (2023).","journal-title":"Front. Oncol."},{"key":"67415_CR46","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1080\/14656566.2021.1948013","volume":"22","author":"D Raj","year":"2021","unstructured":"Raj, D. et al. Pharmacological strategies for improving the prognosis of glioblastoma [J]. Expert Opin. Pharmacother. 22, 2019\u20132031 (2021).","journal-title":"Expert Opin. Pharmacother."},{"key":"67415_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","volume":"623","author":"AL Ling","year":"2023","unstructured":"Ling, A. L. et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma [J]. Nature 623, 157\u2013166 (2023).","journal-title":"Nature"},{"key":"67415_CR48","doi-asserted-by":"publisher","first-page":"129774","DOI":"10.1016\/j.cej.2021.129774","volume":"421","author":"X Pei","year":"2021","unstructured":"Pei, X. et al. Targeted exosomes for co-delivery of siFGL1 and siTGF-\u03b21 trigger combined cancer immunotherapy by remodeling immunosuppressive tumor microenvironment [J]. Chem. Eng. J. 421, 129774\u2013129790 (2021).","journal-title":"Chem. Eng. J."},{"key":"67415_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jconrel.2022.07.011","volume":"349","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence [J]. J. Control. Release 349, 565\u2013579 (2022).","journal-title":"J. Control. Release"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67415-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67415-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:08:13Z","timestamp":1769216893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67415-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67415"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67415-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"636"}}